ReviewMaterials today. Bio2026
Nanomedicine targeting ECM stiffness: restoring mechanical homeostasis for cancer immunotherapy.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathological stiffening of the extracellular matrix (ECM) in solid tumors drives immunosuppression and therapeutic resistance. However, non-specific ECM degradation has limited clinical benefit and risks promoting metastasis. To address this dilemma, this review proposes a paradigm shift from indiscriminate physical degradation toward spatiotemporally controlled reconstruction of mechanical homeostasis using smart nanomedicine, an approach that lies at the intersection of materials science, cancer biology, and immunotherapy. We first concisely outline how aberrant ECM stiffness drives a vicious cycle of physical immune exclusion, mechanotransduction-mediated immune reprogramming, and reciprocal fibrotic activation. We then critically analyze how advanced nanomedicine platforms can. achieve precise ECM modulation without off-target toxicity. Central to this approach is the "mechano-therapeutic window", an optimal stiffness range that maximizes immune infiltration and therapy sensitization without provoking metastatic risk. Furthermore, we highlight the "priming" strategy, wherein nanomedicine-mediated ECM softening serves as an upstream step to synergistically enhance subsequent immunotherapy, chemotherapy, and radiotherapy, as well as other emerging therapies. Finally, we outline future directions, including the development of adaptive delivery systems that sense and adapt to stiffness dynamics in real-time. By shifting focus from indiscriminate degradation to intelligent mechanical homeostasis, this framework aims to improve cancer immunotherapy outcomes in desmoplastic solid tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.